117 results
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Dec 13
BioLineRx Presents Positive Preclinical Results of
12:00am
as a poster at the 55th Annual Meeting of the American Society of Hematology (ASH). The data show that BL-8040 is efficient in inducing the death of AML … and FLT-3 targeted therapies.
The data presented in the conference show that BL-8040 directly inhibits AML cell growth and induces cell death, both
6-K
EX-99
BLRX
Bioline Rx Ltd
16 Dec 13
BioLineRx Announces Promising Initial Phase 2
12:00am
for BL-8040 show substantial mobilization
of cancer cells and signs of robust cancer cell death (apoptosis) -
Jerusalem, December 16, 2013 – BioLineRx … the vulnerability of the cells to chemotherapy treatment. In addition, signs of robust apoptosis (cell death) of cancer cells were observed following
6-K
EX-99
BLRX
Bioline Rx Ltd
11 Dec 18
BioLineRx Announces Initiation of Triple Combination Arm of
7:00am
immunogenic cell death, leading to activation and expansion of new tumor-reactive T-cells. Based on its mechanism of action, we believe that BL-8040 may … and to be effective at inducing direct tumor cell death. In addition, clinical findings have demonstrated the ability of BL-8040 to mediate infiltration
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Apr 13
BioLineRx Receives Regulatory Approval to Commence
12:00am
to evaluate the capabilities of BL-8040 in mobilizing cancer cells from the bone marrow to the peripheral blood, and in inducing their cell death … apoptosis (cell death). Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Apr 14
Current report (foreign)
12:00am
-8040 - its ability to mobilize cells from the bone marrow into the peripheral blood system, and its ability to induce cancer cell death directly … and by mobilizing leukemic stem cells from the bone marrow’s protective niches and sensitizing them to Imatinib-induced cell death.”
About BL-8040
BL-8040
6-K
EX-99
cqr54rd
6 Jun 13
Current report (foreign)
12:00am
6-K
EX-99
1mwa8k7mf 75x90e9
19 Oct 18
BioLineRx Presents Top-Line Results from
7:00am
6-K
EX-99.1
fvy24ra 0hl8ff
5 Mar 15
Current report (foreign)
12:00am
6-K
EX-99
n1o2pvyu89il16ud
9 Sep 13
BioLineRx’s BL-8040 Receives Orphan Drug
12:00am
6-K
EX-99
hw0kaefpwryar22
17 Sep 14
Current report (foreign)
12:00am
6-K
EX-99
uv47fqwnaa6
22 Oct 18
Current report (foreign)
7:00am
6-K
EX-99
o3vdwz
8 Dec 14
BioLineRx Reports Positive Data from Ongoing Phase 2a
12:00am
6-K
EX-99.1
xi8hh8xnxtx
4 Sep 12
Current report (foreign)
12:00am
6-K
EX-99
frx525j
27 Jul 15
BioLineRx Announces Top-Line Results from
12:00am
6-K
EX-99.1
n9fsrm5p1vj9i
3 Mar 14
Current report (foreign)
12:00am
6-K
EX-99
jgammum
3 Sep 13
BioLineRx Announces Issuance of United States Patent
12:00am
6-K
EX-99
0dexc4m nf26u1rv913
19 Nov 13
BioLineRx Reports Publication in Peer Review Journal
12:00am
6-K
EX-99
ujdy yq2q
14 Mar 14
BioLineRx Announces Issuance of United States Patent
12:00am
6-K
EX-99
4mm69
18 Oct 17
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040
12:00am
6-K
EX-99
jlihn0
23 Jan 14
BioLineRx Receives Orphan Drug
12:00am